Can-Fite BioPharma (NYSE:CANF) Downgraded by StockNews.com

Can-Fite BioPharma (NYSE:CANF) was downgraded by investment analysts at StockNews.com from a “hold” rating to a “sell” rating in a note issued to investors on Wednesday.

Separately, EF Hutton Acquisition Co. I upgraded shares of Can-Fite BioPharma to a “strong-buy” rating in a research report on Wednesday, July 17th.

Can-Fite BioPharma Trading Down 3.7 %

Shares of CANF stock opened at $2.32 on Wednesday. The company has a market capitalization of $8.21 million, a price-to-earnings ratio of -1.30 and a beta of 1.41. The firm has a 50-day moving average price of $2.29 and a 200 day moving average price of $2.51. Can-Fite BioPharma has a twelve month low of $1.83 and a twelve month high of $4.69.

Institutional Trading of Can-Fite BioPharma

A hedge fund recently raised its stake in Can-Fite BioPharma stock. Armistice Capital LLC lifted its stake in shares of Can-Fite BioPharma Ltd. (NYSE:CANF) by 35.5% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 518,853 shares of the company’s stock after acquiring an additional 136,055 shares during the period. Armistice Capital LLC owned 14.66% of Can-Fite BioPharma worth $1,339,000 as of its most recent SEC filing. 21.00% of the stock is owned by institutional investors.

About Can-Fite BioPharma

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.